SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-101174"
 

Search: onr:"swepub:oai:DiVA.org:oru-101174" > Low Serum BAFF Conc...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hernández-Breijo, BorjaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain (author)

Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-09-02
  • MDPI,2022
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-101174
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-101174URI
  • https://doi.org/10.3390/jcm11175207DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:150694324URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding agencies:Professor Nanna Svartz Foundation 2020-00368Ulla and Roland Gustafsson Foundation 2021-26Nordic Pharma 20181129NGBV
  • We investigated B-cell-activating factor (BAFF) in relation to response to treatment with TNF inhibitors (TNFis) in rheumatoid arthritis (RA). This was a longitudinal study including 158 patients with RA treated with TNFis and followed up for 6 months. Clinical response at 6 months of treatment was defined according to the EULAR criteria for good responders (GRs). BAFF concentration was measured in serum samples, collected at baseline and at 6 months. Associations with EULAR response were evaluated using univariable and multivariable logistic regression models. ROC analysis was performed to determine the optimal threshold of serum BAFF concentration associated with good EULAR response to treatment. After 6 months of TNFi treatment, 24% of patients were GRs. They had a lower BMI, lower baseline DAS28 and lower baseline serum BAFF concentration than non-responders. After 6 months of TNFi treatment, autoantibody-positive patients who attained GR had significantly lower serum BAFF concentrations compared with patients who did not. Serum BAFF < 968 pg/mL at 6 months represented the concentration likely to best discriminate between GR and non-GR at 6 months of TNFi treatment. Autoantibody-seropositive patients who had serum BAFF < 968 pg/mL at 6 months demonstrated a more than four-fold increased probability to be GRs compared with patients with higher BAFF concentrations. In conclusion, serum BAFF concentrations were associated with response to TNFis in seropositive RA patients, corroborating the importance of the B-cell compartment in RA.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Parodis, Ioannis,1981-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden(Swepub:oru)isps (author)
  • Novella-Navarro, MartaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Rheumatology, La Paz University Hospital, Madrid, Spain (author)
  • Martínez-Feito, AnaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Immunology Unit, La Paz University Hospital, Madrid, Spain (author)
  • Navarro-Compán, VictoriaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Rheumatology, La Paz University Hospital, Madrid, Spain (author)
  • Díaz-Almirón, MarianaBiostatistics Unit, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain (author)
  • Pascual-Salcedo, DoraImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain (author)
  • Balsa, AlejandroImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Rheumatology, La Paz University Hospital, Madrid, Spain (author)
  • Plasencia-Rodríguez, ChamaidaImmuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain; Rheumatology, La Paz University Hospital, Madrid, Spain (author)
  • Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, SpainInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Journal of Clinical Medicine: MDPI11:172077-0383

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view